Azmasol HFA 100

Description:

Azmasol® HFA inhaler is an environment friendly, CFC-free inhaler.
It contains Salbutamol BP (as sulfate) as the active ingredient which is a ß2-
adrenoceptor agonist used in the treatment of asthma and other forms of diffuse
reversible airways obstruction.

Indication:

Azmasol® HFA (Salbutamol) inhaler is indicated for the treatment and prophylaxis of bronchial asthma and for the treatment of reversible airways obstruction associated with bronchitis and
emphysema. Azmasol® HFA (Salbutamol) inhaler may be used to relieve attacks of acute dyspnoea and may also be taken prophylactically before exertion or to prevent exercise-induced asthma. It is suitable for treating bronchospasm in patients with coexisting heart disease or hypertension, including those taking beta blockers, because of its selective action on the bronchial receptors and lack of effects on the cardiovascular system. Salbutamol is a sympathomimetic agent which has a highly selective action on beta adrenergic receptors in bronchial muscle. At therapeutic levels, it has little effect on cardiac receptors.

Dosage:
Adults: For the relief of acute bronchospasm and for managing intermittent
episodes of asthma: one or two inhalation as a single dose; for chronic
maintenance or prophylactic therapy: two inhalations three or four times daily; for
prevention of exercise induced bronchospasm : two inhalations before exertion.
Children: for the relief of acute bronchospasm, management of episodic asthma
and for prevention of exercise induced bronchospasm: one inhalation; for routine
maintenance and prophylaxis: one inhalation three or four times daily, increasing
if necessary to two inhalations three or four times daily. Elderly: The dosage is the
same as that for adults.

Side Effects:

Mild tremor and headache have been
rarely reported. These usually disappear with continuous treatment. There have
been very rare reports of transient muscle cramp. Hypersensitivity reactions
including angioedema, urticaria, bronchospasm, hypotension and collapse have
been reported very rarely. As with other inhalation therapy, the potential for
paradoxical bronchospasm should be kept in mind. If it occurs, the preparation
should be discontinued immediately and alternative therapy should be instituted.